Transitioning to Adjuvant Therapy in EGFR-Mutated NSCLC

In this segment, Dr. Alexander Spira and Dr. Ticiana Leal discuss how to approach the transition from neoadjuvant therapy to the adjuvant setting in early-stage EGFR-mutated non–small cell lung cancer (NSCLC). Dr. Leal highlights the importance of reassessing patients after surgery, including recovery status, pathologic findings, and overall treatment goals, to guide next steps. The conversation focuses on how clinicians counsel patients regarding the rationale for continuing therapy in the adjuvant setting, particularly in the context of prolonged treatment duration. Dr. Leal emphasizes the need to clearly communicate expectations, reinforce the goal of reducing recurrence risk, and support patients through the transition from active surgical management to longer-term systemic therapy. The segment also underscores the importance of coordination across the multidisciplinary team to ensure continuity of care. This discussion highlights how thoughtful planning and patient education are essential in optimizing outcomes in EGFR-mutated NSCLC.